Digging Into What Hershey and Eli Lilly Told Investors
Eli Lilly 's blockbuster weight loss drugs, and questions about its valuation. Then, Ricky continues his conversation with ...
What’s ahead for Eli Lilly and Novo as RFK Jr. takes over HHS
Eli Lilly (LLY) stock and Novo Nordisk (NVO) stock face investor scrutiny as RFK Jr. takes the leadership of HHS. Read more ...
Ibj.com5d
Lebanon planning board to review designs for Lilly’s $4.5B foundry at LEAP District
The 200-acre Lilly Medicine Foundry is expected to add 400 full-time jobs for highly skilled workers, including engineers, ...
GLP-1 Drugs Drive Growth for Eli Lilly. Is the Stock a Buy?
Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.
Eli Lilly and Company (LLY): A Bull Case Theory
We came across a bullish thesis on Eli Lilly and Company (LLY) on Substack by Kontra Investments. In this article, we will ...
Eli Lilly Seeks To Expand Into Cancer Radiopharma And Fatty Liver, With Two Global Deals
Eli Lilly strengthens its pipeline with AdvanCell for targeted alpha therapies and partners with OliX to advance OLX75016 for ...
Hosted on MSN12d
The battle over anti-obesity medications
Rocketing demand, legal disputes, and the future of weight loss were all spurred by a new class of anti-obesity medications.
Eli Lilly price target raised to $1,000 from $997 at BofA
BofA analyst Tim Anderson raised the firm’s price target on Eli Lilly (LLY) to $1,000 from $997 and keeps a Buy rating on the shares after ...
Eli Lilly reports sustained Crohn's disease treatment success
INDIANAPOLIS - Eli Lilly and Company (NYSE: NYSE:LLY), a pharmaceutical giant with a market capitalization of $783.7 billion ...
Nasdaq22d
What Does the Future Hold for Eli Lilly?
With its offering of tirzepatide (branded as Mounjaro and Zepbound), Eli Lilly and Co. (NYSE: LLY) was another key pharma player in this new type of treatment for diabetes and obesity.